| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Agenus Inc (NASDAQ: AGEN)
AGEN Technical Analysis
4
| As on 9th Jun 2023 AGEN SHARE Price closed @ 1.99 and we RECOMMEND Sell for LONG-TERM with Stoploss of 2.49 & Strong Sell for SHORT-TERM with Stoploss of 2.87 we also expect STOCK to react on Following IMPORTANT LEVELS. |
AGENSHARE Price
| Open | 2.06 | Change | Price | % |
| High | 2.13 | 1 Day | -0.05 | -2.45 |
| Low | 1.94 | 1 Week | 0.43 | 27.56 |
| Close | 1.99 | 1 Month | 0.49 | 32.67 |
| Volume | 12259600 | 1 Year | -1.53 | -43.47 |
| 52 Week High 3.58 | 52 Week Low 1.30 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| AGEN Daily Charts |
AGEN Intraday Charts |
Whats New @ Bazaartrend |
AGEN Free Analysis |
|
|
AGEN Important Levels Intraday
| RESISTANCE | 2.36 |
| RESISTANCE | 2.24 |
| RESISTANCE | 2.17 |
| RESISTANCE | 2.09 |
| SUPPORT | 1.89 |
| SUPPORT | 1.81 |
| SUPPORT | 1.74 |
| SUPPORT | 1.62 |
AGEN Forecast April 2024
| 4th UP Forecast | 3.65 |
| 3rd UP Forecast | 3.12 |
| 2nd UP Forecast | 2.79 |
| 1st UP Forecast | 2.46 |
| 1st DOWN Forecast | 1.52 |
| 2nd DOWN Forecast | 1.19 |
| 3rd DOWN Forecast | 0.86 |
| 4th DOWN Forecast | 0.33 |
AGEN Weekly Forecast
| 4th UP Forecast | 2.90 |
| 3rd UP Forecast | 2.61 |
| 2nd UP Forecast | 2.43 |
| 1st UP Forecast | 2.25 |
| 1st DOWN Forecast | 1.73 |
| 2nd DOWN Forecast | 1.55 |
| 3rd DOWN Forecast | 1.37 |
| 4th DOWN Forecast | 1.08 |
AGEN Forecast2024
| 4th UP Forecast | 6.56 |
| 3rd UP Forecast | 5.09 |
| 2nd UP Forecast | 4.19 |
| 1st UP Forecast | 3.28 |
| 1st DOWN Forecast | 0.7 |
| 2nd DOWN Forecast | -0.21 |
| 3rd DOWN Forecast | -1.11 |
| 4th DOWN Forecast | -2.58 |
Agenus Inc ( NASDAQ USA Symbol : AGEN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
AGEN Business Profile
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Address: 3 Forbes Road, Lexington, MA, United States, 02421-7305
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service